The impact of the associated symptoms of other LUTS by tadalafil administration to patients with BPH
- Conditions
- Benign prostatic hyperplasia
- Registration Number
- JPRN-UMIN000020040
- Lead Sponsor
- Kyoto Prefecturral University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 400
Not provided
1. Patients with a history of hypersensitivity to components of tadalafil 2. Patients in the administration of nitrate agent or nitric oxide (NO) donating agent (nitroglycerin, amyl nitrite, nitrate Isozorubido) 3. Patients in the administration of soluble guanylate cyclase (sGC) stimulator (the Riociguat) 4. See the section of the patient ["Other notes" with the next listed cardiovascular system disorders. In addition, there is no experience for these patients. ] (1) patients with unstable angina (2)Patients with heart failure (NYHA classification 3 degrees or more) (3)Patients with uncontrolled arrhythmias, hypotension (blood pressure <90 / 50mmHg), or uncontrolled hypertension (resting blood pressure> 170 / 100mmHg) (4) Patients with a history of myocardial infarction is that within the last three months (5) Patients with a history of cerebral infarction, cerebral hemorrhage that is within the last 6 months 5. Patients with patients 6. severe liver failure 7. with severe renal failure 8. Other, patients attending physician has determined that inadequate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prostate volume, residual urine, IPSS, QOL score, OABSS, NIH Chronic Prostatitis Symptom Index (NIH-CPSI), and IIEF5 Questionnaire will be evaluated before and after additional administration and 4 weeks. In the possible case, voiding diary is also evaluated before and after administration. Also, the side effects will be evaluated by interview
- Secondary Outcome Measures
Name Time Method